GlassScriptPhysician profile
Ashley Streseman
NPI 1821627530
$1,061.56
in general payments reported to CMS, 2019-2025
16 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.63 · 2023: $13.30 · 2024: $732 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,014.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $262.17 | 2024-2025 | |
| Sk Life Science, INC. | $165.47 | 2024 | Xcopri |
| Alexion Pharmaceuticals, INC. | $124.98 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $60.06 | 2024 | Dysport |
| Genentech USA, INC. | $59.28 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Takeda Pharmaceuticals U.S.A., INC. | $56.95 | 2024 | Hyqvia |
| Argenx US, INC. | $46.19 | 2024-2025 | Vyvgart Hytrulo |
| Ucb, INC. | $44.97 | 2024-2025 | Rystiggo, Fintepla |
| Vanda Pharmaceuticals INC. | $43.64 | 2024-2025 | Ponvory |
| Biogen, INC. | $28.46 | 2024 | Skyclarys |
| Genzyme Corporation | $22.77 | 2024 | |
| Cycle Pharmaceuticals INC | $22.21 | 2025 | Tascenso Odt, Bafiertam |
| Abbvie INC. | $21.09 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $20.71 | 2025 | |
| Csl Behring | $19.03 | 2024 | Hizentra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.65 | 2024 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Streseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.